Topical summits in Dubai, Berlin, Nanjing, Basel, Lisbon, London and other cities discussed the uniqueness of Dr Allen's ...

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) procedures in Arizona using the Vanquish® Water ...

Therapeutic Dr Allen’s Devices are designed to treat different chronic health conditions, including kidney stones (known as ...

The Trump administration wants Americans to have more conversations with their physicians. But it also can’t seem to stop ...

The European Parliament has reportedly blocked lawmakers from using the baked-in AI tools on their work devices, citing cybersecurity and privacy risks with uploading confidential correspondence to ...

The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

HSHS St. Elizabeth’s Hospital is proud to announce the 100th Aquablation therapy procedure, marking a significant milestone ...

Global Urology Devices Market OverviewThe global urology devices market is poised for steady expansion and is projected to grow at a CAGR of approximately 6–7% during the forecast period from 2024 to ...